Earnings

Should You Invest in Northwest Biotherapeutics (NWBO)? A Look at the Insider Trends

Recent insider trends for Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) have caught the attention of investors. Insider activity is often a strong indicator of future performance in a stock, and if the data on NWBO is anything to go by, investors should pay attention.

Institutions own 00.01% of Northwest Biotherapeutics, Inc. (NWBO)’s shares. The total value of these holdings, in millions, is $0. Among active positions in the latest quarter, 0 holders increased their positions by a total of 0 shares, 2 holders decreased the positions by a total of 95717 shares, and 2 holders held their positions. This works out to a net decrease in ownership of 95717 shares, and suggests that institutions are feeling bearish about the stock.

Among new and sold out positions, 0 holders initiated new positions by a total of 0 shares and 2 holders exited their positions by a total of 95717 shares. This nets out to a decrease of 95717 shares and is another bearish sign for NWBO.

Comparing the number of shares sold short over time is a method analysts often use to get a reading on investor sentiment. Northwest Biotherapeutics, Inc. (NASDAQ:NWBO)’s short interest is 3.69 million shares, or % of the float. This represents an increase of 8% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.



Supplementing insider data with technical indicators can help an investor form a more complete view on the outlook for a stock. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that NWBO is a sell, which implies that NWBO is expected to underperform the market based on prior trading patterns.

Conclusion

Institutional ownership trends suggest that the stock is expensive and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) is overvalued.

Previous ArticleNext Article

Related Post

A Side-by-side Analysis of Netflix, Inc. (NFLX) an... Netflix, Inc. (NASDAQ:NFLX) shares are up more than 55.66% this year and recently increased 3.47% or $6.47 to settle at $192.71. Discovery Communicati...
Comparing Flowserve Corporation (FLS) and Gardner ... Flowserve Corporation (NYSE:FLS) shares are down more than -14.40% this year and recently decreased -0.10% or -$0.04 to settle at $41.13. Gardner Denv...
Why You Should Still Buy Dr. Reddy’s Laborat... Dr. Reddy's Laboratories Limited (NYSE:RDY) gained 5.72% in yesterday’s day, going up from its prior closing price of $35.68 to $37.72, and has now re...
VEREIT, Inc. (VER) Stock Nears $8.53: Still a Buy? VEREIT, Inc. (NYSE:VER) gained 1.07% in the first business day of September, going up from its prior closing price of $8.44 to $8.53, and has now reco...
Immune Pharmaceuticals, Inc. (IMNP): Can the Bear ... Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) fell by -11.03% in Friday’s trading session from $1.45 to $1.29 and has now fallen 3 consecutive sessions. ...